

Complete Genome Sequence of *Mycobacterium vaccae* Type Strain ATCC 25954

Yung S. Ho,^a Sabir A. Adroub,^a Maram Abadi,^a Bader Al Alwan,^a Reham Alkhateeb,^a Ge Gao,^a Alaa Ragab,^a Shahjahan Ali,^b Dick van Soolingen,^{c,d} Wilbert Bitter,^e Arnab Pain,^a and Abdallah M. Abdallah^a

Pathogen Genomics Laboratory, King Abdullah University of Science and Technology, Thuwal-Jeddah, Kingdom of Saudi Arabia^a; Bioscience Core Laboratory, King Abdullah University of Science and Technology, Thuwal-Jeddah, Kingdom of Saudi Arabia^b; Dutch National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands^c; Department of Clinical Microbiology and Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands^d; and Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands^e

***Mycobacterium vaccae* is a rapidly growing, nontuberculous *Mycobacterium* species that is generally not considered a human pathogen and is of major pharmaceutical interest as an immunotherapeutic agent. We report here the annotated genome sequence of the *M. vaccae* type strain, ATCC 25954.**

There is an increasing interest in the role of nontuberculous mycobacteria (NTM) as pathogens causing pulmonary disease and disseminated disease in both immunocompetent and immunocompromised individuals. NTM species previously considered nonpathogenic have now been shown to cause disease in humans. *Mycobacterium vaccae*, a rapidly growing and yellow-pigmented NTM, was first isolated, described, and named in 1962 (4). This bacterium can be isolated from the environment, including soil and water and especially in contact with cattle, as well as from bovine lactic ducts, skin nodules, and milk products (13). Because of the strong association of this *Mycobacterium* species with cattle, it was named *M. vaccae*, as *vaccae* is the Latin word for cow. *M. vaccae*, previously considered nonpathogenic, has been associated rarely with pulmonary infections and soft tissue infections (5). However, *M. vaccae* is mainly being studied for use as an immunotherapeutic agent together with chemotherapy in the treatment of tuberculosis and other diseases, such as cancer, asthma, atopic dermatitis, and psoriasis (2, 6, 7, 9, 10). To better understand the molecular basis of *M. vaccae* and further study phylogenetic relationships and the genetic factors responsible for pathogenicity, we determined the complete genome sequence of this microorganism. Whole-genome sequencing is also important to facilitate a more reliable genetic identification between and within *Mycobacterium* species.

The whole-genome sequencing of the *M. vaccae* type strain, ATCC 25954, was performed on the Illumina HiSeq2000 platform using a 100-bp paired-end library with an insert size of 500 bp. A total of 24.7 million Illumina sequencing reads were generated. These short sequence reads were quality trimmed before being *de novo* assembled using velvet (14). The genome was further improved with ICORN (8) and IMAGE (12) as described in PAGIT (11) before it was scaffolded with SSPACE (3). The final assembly has 33 supercontigs and an N_{50} of 383,962 bp. The genome annotation was performed using the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP).

The *M. vaccae* type strain ATCC 25954 genome sequence is 6,245,372 bp in length, with 5,949 predicted coding sequences. The overall GC content of the chromosome amounted to 68.5%. There are 49 tRNA-encoding genes and six sets of rRNA operons as predicted by the PGAAP pipeline. It was possible to assign a

biological function to 71% (4,220) of the coding sequences on the *M. vaccae* chromosome.

The automated annotation of this genome by the RAST server (1) revealed that *M. vaccae* is most closely related to *Mycobacterium vanbaalenii* PYR-1, compared to all mycobacteria with complete genome sequences currently available. Furthermore, RAST annotation revealed that this genome may contain many genes encoding proteins that are categorized in the subsystem category of amino acids and derivatives (583 genes), followed by cofactors, vitamins, prosthetic groups, and pigments (371 genes). There are 57 genes encoding products that may be involved in virulence, disease, and defense, of which 37 are linked with resistance to antibiotics and toxic compounds, 12 are involved in invasion and intracellular resistance, and 8 are linked with antimicrobial products, such as bacteriocins.

Nucleotide sequence accession numbers. This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number ALQA00000000. The version described in this paper is the first version, ALQA00000000.

ACKNOWLEDGMENT

This work was supported by faculty funding to A.P. by King Abdullah University of Science and Technology.

We thank the Dutch National Institute for Public Health and the Environment (RIVM) for providing the strain. We gratefully acknowledge the support of Roy Ummels at the Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, and Tridia van der Laan from the RIVM, Bilthoven, the Netherlands.

REFERENCES

1. Aziz RK, et al. 2008. The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. doi:10.1186/1471-2164-9-75.
2. Balagon MV, et al. 2000. Improvement in psoriasis after intradermal administration of heat-killed *Mycobacterium vaccae*. *Int. J. Dermatol.* 39:51–58.

Received 13 August 2012 Accepted 10 September 2012

Address correspondence to Abdallah M. Abdallah, abdallah.abdallah@kaust.edu.sa.

Copyright © 2012, American Society for Microbiology. All Rights Reserved. doi:10.1128/JB.01462-12

3. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. 2011. Scaffolding pre-assembled contigs using SSPACE. *Bioinformatics* 27: 578–579.
4. Boenickse R, Juhasz SE. 1964. Beschreibung der neuen Species *Mycobacterium vaccae* no. sp. *Zentralbl. Bakteriol. Orig.* 192:133–135.
5. Hachem R, et al. 1996. Cutaneous and pulmonary infections caused by *Mycobacterium vaccae*. *Clin. Infect. Dis.* 23:173–175.
6. Hadley EA, et al. 2005. Effect of *Mycobacterium vaccae* on cytokine responses in children with atopic dermatitis. *Clin. Exp. Immunol.* 140: 101–108.
7. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalglish AG. 1998. Immunotherapy of advanced prostate cancer: a phase I/II trial using *Mycobacterium vaccae* (SRL172). *Br. J. Urol.* 82:568–573.
8. Otto TD, Sanders M, Berriman M, Newbold C. 2010. Iterative Correction of Reference Nucleotides (iCORN) using second generation sequencing technology. *Bioinformatics* 26:1704–1707.
9. Shirtcliffe PM, Goldkorn A, Weatherall M, Tan PL, Beasley R. 2003. Pilot study of the safety and effect of intranasal delipidated acid-treated *Mycobacterium vaccae* in adult asthma. *Respirology* 8:497–503.
10. Stanford J, Stanford C, Grange J. 2004. Immunotherapy with *Mycobacterium vaccae* in the treatment of tuberculosis. *Front. Biosci.* 9:1701–1719.
11. Swain MT, et al. 2012. A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs. *Nat. Protoc.* 7:1260–1284.
12. Tsai IJ, Otto TD, Berriman M. 2010. Improving draft assemblies by iterative mapping and assembly of short reads to eliminate gaps. *Genome Biol.* 11:R41. doi:10.1186/gb-2010-11-4-r41.
13. Wayne LG, Kubica GP. 1986. The mycobacteria, p 1435–1457. *In* Holt JG, Sneath PH, Mair NS, Sharpe ME (ed), *Bergey's manual of systematic bacteriology*, vol 2. Williams & Wilkins, Baltimore, MD.
14. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome Res.* 18:821–829.